Biosimilar Players Will Be Manufacturers Large And Small, Analyst Predicts

The biosimilar manufacturing and development process has been optimized to ensure multiple companies can enter the market, Sanford C. Bernstein & Co. Senior Health Care Analyst Ronny Gal argues, but uncertainty will remain until FDA designs its approval system.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet